Profound Medical's TULSA-PRO Shows Superior Erectile Function Preservation vs Robotic Surgery in CAPTAIN Trial
PROF sits 42% above its 52-week low of $4.8 on elevated volume (2.0× avg).
Summary
Profound Medical presented five abstracts at the 15th Interventional MRI Symposium, including CAPTAIN trial data showing TULSA-PRO patients were more than twice as likely to preserve erectile function and continence versus robotic surgery.
Key Events · Product Development and Regulatory · PROF
-
CAPTAIN Trial: Superior Functional Outcomes
Whole-gland TULSA patients were more than twice as likely to preserve both erectile function and pad-free continence vs robotic RP at six months (risk ratio 2.1; p=0.004).
-
Real-World Validation from Mayo Clinic
Mayo Clinic Florida reported 100% pad-free continence and 87.5% erection preservation beyond 12 months in 58 patients; Rochester showed 62-66% sustained PSA reduction in 41 patients.
-
CARE Registry: 197-Patient Analysis
Median PSA nadir ranged from 0.23 ng/mL (whole-gland) to 1.10 ng/mL (focal), demonstrating treatment flexibility with no significant difference in biochemical recurrence rates.
-
Platform Expansion: Siemens 0.55T Free.Max
Technical feasibility validated on lower-field-strength MRI with 40% improved temperature-measurement precision; not yet FDA-cleared for this combination.
Analysis · PROF · Industrial Applications And Services
The CAPTAIN randomized controlled trial data is the headline: whole-gland TULSA patients were more than twice as likely to preserve both erectile function and pad-free continence compared with robotic radical prostatectomy at six months (risk ratio 2.1; p=0.004). This is the first fully enrolled multicenter RCT directly comparing TULSA to robotic RP, and the statistically superior functional outcomes address the primary concern that has historically limited prostate ablation adoption. The real-world data from Mayo Clinic (100% pad-free continence, 87.5% erection preservation) and the CARE Registry (197 patients) reinforce reproducibility outside trial settings. The Siemens 0.55T Free.Max technical validation is a longer-term platform expansion story — if commercialized, it could lower infrastructure barriers and broaden the installed-base opportunity. Against the backdrop of the company's Q3 revenue pre-announcement of $9.8M-$10.0M (up 85-89% YoY) just one week ago, this clinical evidence strengthens the commercial narrative for TULSA-PRO adoption.
How filings like this one have moved
In the 30 days to Oct 31, 2026, 31.5% of the 1750 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, PROF was trading at $6.83 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $256.1M. The 52-week trading range was $4.80 to $8.95. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.